Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | BRAF |
Variant | G469A |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | BRAF G469A is a hotspot mutation within the protein kinase domain of the Braf protein (UniProt.org). G469A results in increased Braf kinase activity and downstream activation of Erk, and is transforming in cell culture (PMID: 19010912, PMID: 12068308, PMID: 29533785). |
Associated Drug Resistance | |
Category Variants Paths |
BRAF mutant BRAF act mut BRAF G469A BRAF mutant BRAF G469X BRAF G469A |
Transcript | NM_004333.6 |
gDNA | chr7:g.140781602C>G |
cDNA | c.1406G>C |
Protein | p.G469A |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001378467.1 | chr7:g.140781611C>G | c.1406G>C | p.G469A | RefSeq | GRCh38/hg38 |
NM_001354609.2 | chr7:g.140781602C>G | c.1406G>C | p.G469A | RefSeq | GRCh38/hg38 |
NM_004333 | chr7:g.140781602C>G | c.1406G>C | p.G469A | RefSeq | GRCh38/hg38 |
NM_004333.6 | chr7:g.140781602C>G | c.1406G>C | p.G469A | RefSeq | GRCh38/hg38 |
XM_005250045 | chr7:g.140781602C>G | c.1406G>C | p.G469A | RefSeq | GRCh38/hg38 |
NM_004333.5 | chr7:g.140781602C>G | c.1406G>C | p.G469A | RefSeq | GRCh38/hg38 |
NM_001378470.1 | chr7:g.140778000C>G | c.1406G>C | p.G469A | RefSeq | GRCh38/hg38 |
NM_001378474.1 | chr7:g.140781602C>G | c.1406G>C | p.G469A | RefSeq | GRCh38/hg38 |
XM_047420769.1 | chr7:g.140781602C>G | c.1406G>C | p.G469A | RefSeq | GRCh38/hg38 |
NM_001354609.1 | chr7:g.140781602C>G | c.1406G>C | p.G469A | RefSeq | GRCh38/hg38 |
NM_001378468.1 | chr7:g.140781602C>G | c.1406G>C | p.G469A | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03843775 | Phase Ib/II | Binimetinib + Encorafenib | A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers | Completed | USA | 0 |